Your session is about to expire
← Back to Search
Radiolabeled Monoclonal Antibody + Chemotherapy Before Stem Cell Transplant for Hodgkin Lymphoma
Study Summary
This trial is looking at the side effects and best dose of a cancer treatment that uses a radiolabeled monoclonal antibody, which attaches to cancer cells and delivers a cancer-killing substance, in conjunction with chemotherapy drugs. The trial is for patients whose Hodgkin lymphoma hasn't responded to treatment or has returned after treatment.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have experienced a second or later relapse of your condition, regardless of whether you have fully recovered or not after receiving additional treatment.
- Group 1: Treatment (radiolabeled monoclonal antibody, chemotherapy)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Does this research encompass elderly individuals aged 85 or above?
"This clinical study has a minimum age of eligibility set at 18 and the maximum age limit is 70 years old."
Has this pharmaceutical research met the requirements of the FDA?
"The safety of this pharmacological study was rated a 1, as there is only minimal data available to evaluate its efficacy and potential risks."
Are there any remaining vacancies for enrolment in this study?
"It appears that the post on clinicaltrials.gov reveals that this trial is no longer actively looking for participants. It was first published in November 2012 and last updated March 2022, leaving plenty of other trials (2305 to be precise) available for recruitment as we speak."
Is there a possibility for me to join this experiment?
"Eligibility requirements for this study necessitate that participants have hodgkin's disease and are between 18-70 years old. Aproximately 25 patients need to be enrolled in the trial."
What is the participant enrollment for this trial?
"Currently, this medical trial is not actively seeking participants. It was first posted on November 9th 2012 and its information was last updated on March 17th 2022. Should you be searching for other studies, there are 1,724 trials recruiting patients with Hodgkin Disease and 581 pharmaceutical studies currently enrolling subjects."
What ailments have been successfully treated through pharmacological analysis?
"Hematopoietic stem cells are commonly managed with pharmacological study, and this method of treatment can also prove effective for merkel cell cancer, meningeal leukemia, and prostate cancer."
Has there been any past research regarding the effects of pharmaceuticals?
"Currently, there are 581 pharmacological studies being conducted. 142 of them have progressed to Phase 3 and the majority take place in Ann Arbor, Michigan; however, 22318 medical institutions all over the globe are running trials for this medication."
Share this study with friends
Copy Link
Messenger